#obesity

#obesity

Changes in fat cells' epigenome contribute to long-term challenges in maintaining weight loss after obesity.

Physicians are increasingly using new obesity drugs, signaling their effectiveness and potential impact on health.

GLP-1 agonists could lead to a healthier society by reducing obesity and related health issues by 2030.

Fat cells have a biological 'memory' of obesity that complicates weight maintenance post-dieting.

Obesity has a biological memory that complicates weight loss maintenance even after interventions.

Oprah Winfrey's perspective on weight and hunger changed after using GLP-1 drugs, challenging misconceptions about thin people and willpower.

GLP-1 drugs are potentially reversing America's obesity crisis with projected usage rising to 18 million by 2029.

GLP-1 weight-loss drugs may pose risks to vision, highlighting an ironic medical paradox.

Nearly 75% of American adults are obese or overweight, with ultraprocessed foods being a significant concern.

High-fructose corn syrup (HFCS) is metabolized differently than table sugar, contributing to obesity.

HFCS's lax label regulations mislead consumers about its presence in food products.

Obesity is a multifaceted condition arising from various factors, including diet, psychology, and genetics.

Raineri's study experience illuminated the contrasting effects of ultra-processed foods on health, challenging his prior beliefs about diet and obesity.

Weight stigma may hinder healthy living for individuals with obesity, requiring a shift in healthcare focus.

The US obesity rate is trending downward, suggesting potential positive change in the obesity epidemic.

Obesity diagnosis needs to move beyond BMI, focusing on more accurate health assessments.

Reevaluating obesity diagnosis is crucial as BMI alone may misclassify individuals, leading to health risks going unnoticed or false diagnoses.

Obesity should be assessed by body fat and medical complications, not just BMI.

The ad for Hims & Hers promotes weight-loss drugs while minimizing discussions of safety, leading to backlash from lawmakers and health professionals.

Trump's nomination of Kennedy for Health and Human Services may shift focus from pharmaceuticals to nutrition in fighting obesity.

Social interactions significantly influence the composition of gut microbiomes among individuals, suggesting health can be shaped by social relationships.

Obesity rates in the U.S. showed a slight decline from 46% to 45.6%, marking the first decrease in over a decade.

Emerging obesity treatments like orforglipron and retatrutide show significant potential, possibly transforming the landscape of weight loss drugs in 2025.

Verdiva has raised $410 million to develop oral drugs for obesity, challenging established players by addressing unmet medical needs in weight loss.

The Biden administration proposes covering weight-loss injectables under Medicare and Medicaid, potentially aiding millions of obese Americans.

The Biden administration aims to provide free weight loss drugs to low-income individuals and retirees to combat obesity.

New Medicare and Medicaid rule could cover popular weight-loss drugs for millions of obese Americans, representing a significant shift in healthcare policy.

Intermuscular fat increases the risk of heart attacks and heart failure, regardless of BMI.

Obesity is a serious health issue affecting various organs and increasing disease risks, necessitating better diagnosis methods beyond just BMI.

New guidelines aim to redefine obesity diagnosis beyond BMI, utilizing objective health measures.

Two new categories, clinical and pre-clinical obesity, assist in better categorizing obesity-related health risks.

Emphasis on stigma-free treatment approaches for all individuals living with obesity.

Obesity is a significant public health challenge affecting over half of adults in many OECD countries, with the U.S. having the highest rates.

Obesity rates in the U.S. have risen dramatically, with major public health implications for the future.

Diabetes cases have doubled globally in the last 30 years, reaching 800 million, with significant increases in low and middle-income countries.

Kennedy's nomination raises public health concerns due to his extreme and unfounded ideas about health policy.

New front-of-package nutrition labels aim to reduce obesity and diet-related illnesses by highlighting excess sugar, salt, and saturated fat.

A group of researchers advocates for a redefinition of obesity to better capture its complexity, moving beyond traditional BMI measurements.

BMI is an inadequate measure for diagnosing obesity and health risks.

Experts advocate for a more comprehensive assessment of health beyond just weight.

BMI is an imperfect tool indicating obesity and should be replaced or supplemented with better metrics.

Obesity can be categorized into clinical and preclinical to improve diagnosis and treatment.

A new framework for obesity diagnosis offers a more objective and globally applicable method.

A committee has proposed redefining obesity to include more metrics beyond BMI, aiming for a better assessment of body composition.

Medicare and Medicaid are expanding access to anti-obesity drugs, addressing a significant barrier in treating obesity for millions of Americans.

Biden administration proposes Medicare and Medicaid coverage for obesity medications, allowing millions more Americans to access treatment for obesity.

Novo Nordisk's Wegovy drug now costs $193 in China, significantly lower than the $1,350 in the US, raising concerns over pharmaceutical pricing disparities.

Kimchi may aid in weight management and gut health for overweight adults, suggesting its potential as a dietary solution for obesity.

Cannabis is being researched for its potential in weight management and combating obesity.

Trump's administration may target unhealthy food labeling and ingredients due to a growing demand for transparency and healthier options.

Bernie Sanders is advocating for warning labels on ultra-processed foods to promote healthier choices and combat rising obesity rates among children.

Wegovy's price in China is substantially lower than in the US, highlighting global disparities in drug pricing.

A new weight-loss jab, Mounjaro, will be rolled out on the NHS, but the implementation may take up to 12 years due to service capacity concerns.

Robert F. Kennedy Jr. argues that access to healthy food is key to solving obesity and diabetes, criticizing reliance on drug treatments like Ozempic.

Cardiorespiratory fitness is a stronger predictor of mortality risk than body mass index (BMI).

Obese individuals who are fit have similar mortality risks as normal weight individuals who are fit.

Obesity in the U.S. military surged during the COVID-19 pandemic, impacting readiness and increasing health-related costs significantly.